Medical equipment maker Revvity handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting on continued strength in its diagnostics business even as weakness in academic research funding persists.
Life sciences firms are riding a wave of improving conditions in the pharmaceutical market and easing policy uncertainty, cushioning the impact of subdued spending by universities and research institutions.
Sign up here.
Revvity now expects 2026 adju… [1060 chars]
Source: Reuters | Published: 2026-02-02T12:13:35Z
Credit: Reuters
